BIOVF (Swedish Orphan Biovitrum AB) Tariff Resilience Score: 8/10 (As of Jul. 09, 2026)


BIOVF Swedish Orphan Biovitrum AB BIOVF
83 GF Score
Price $48.00
GF Value $34.87
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Swedish Orphan Biovitrum AB Tariff Resilience Score?

Swedish Orphan Biovitrum AB BIOVF 83 Tariff Resilience Score is 8 as of Jul. 09, 2026. GuruFocus rates BIOVF with a GF Score™ of 83/100 and a GF Value™ of $34.87 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,029 Drug Manufacturers companies, Swedish Orphan Biovitrum AB ranks better than 99.61% on this metric.

Swedish Orphan Biovitrum AB has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Swedish Orphan Biovitrum AB has Swedish Orphan Biovitrum AB has a strong global presence with diversified markets. It benefits from industry-specific exemptions and has shown resilience to past tariff changes.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Swedish Orphan Biovitrum AB might have Highly Resilient.

Swedish Orphan Biovitrum AB  (OTCPK:BIOVF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Swedish Orphan Biovitrum AB Tariff Resilience Score Related Terms

BIOVF vs ZTS, UTHR: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Swedish Orphan Biovitrum AB Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Tariff Resilience Score falls into.


BIOVF
83GF Score
Swedish Orphan Biovitrum AB BIOVF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Swedish Orphan Biovitrum AB (BIOVF) has a Tariff Resilience Score of 8 as of Jul. 09, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #4 out of 1029 companies in the Drug Manufacturers industry, placing it in the top 0.40000000000001%.
Is Swedish Orphan Biovitrum AB's Tariff Resilience Score too high?
Swedish Orphan Biovitrum AB's current Tariff Resilience Score is 8. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #4 out of 1029 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 83/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's Tariff Resilience Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #4 out of 1029 companies for Tariff Resilience Score. This places Swedish Orphan Biovitrum AB in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Swedish Orphan Biovitrum AB's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (BIOVF) is currently considered Significantly Overvalued. The stock's GF Value™ is $34.87, compared to a current price of $48.00 — trading 37.7% above its estimated fair value. The current Tariff Resilience Score is 8. Swedish Orphan Biovitrum AB's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (BIOVF), the current Tariff Resilience Score is 8 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Swedish Orphan Biovitrum AB (BIOVF) Overvalued in 2026?

Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued. The current stock price of $48.00 is trading 37.7% above its estimated GF Value™ of $34.87. GuruFocus considers Swedish Orphan Biovitrum AB to be Significantly Overvalued.

Key valuation signals for BIOVF:

  • Tariff Resilience Score: 8
  • GF Value™: $34.87 vs. price of $48.00 (37.7% above fair value)
  • GF Score™: 83/100 with 6 warning signs

No single metric tells the full story. See the BIOVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Swedish Orphan Biovitrum AB Business Description

Address Norra Stationsgatan 93A, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
83GF Score

Get the complete analysis for BIOVF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$48.00
Price
$34.87
GF Value